Recurrent urinary tract infections (rUTIs) are among the most common bacterial infections worldwide and primarily affect women. While antibiotics remain the standard treatment, frequent recurrences and rising antibiotic resistance highlight the need for alternative therapeutic approaches such as phage therapy.
Phages are little viruses, which selectively target bacteria and effectively destroy even multi-drug resistant bacteria. A new study combining phage therapy (PT) with fecal microbiota transplantation (FMT) to treat recurrent urinary tract infection has been published in Nature Microbiology.
Phage therapy and fecal microbiota transplantation
Researchers from University Hospital Balgrist and University of Zurich, the University of Cologne and University Hospital Cologne, Goethe University Frankfurt and the German Center for Infection Research (DZIF) have for the first time administered a combined phage therapy (PT) with fecal microbiota transplantation (FMT) to decolonize urinary and intestinal reservoirs of rUTI patients.
The novel treatment approach, combining PT and elective FMT, was administered to three female patients with rUTI that did not respond to antibiotics and commonly used non-antibiotic strategies. All had microbiologically confirmed Escherichia coli (E. coli) in multiple infections.
All three women received PT orally and intravesically, i.e., locally applied to the bladder via catheter, for eight days outside of acute episodes at Balgrist. Two of these three patients were elected to receive subsequent FMT in Cologne. Since the bacteria causing the recurring infections often reside in the gut as well as the urinary tract, the FMT treatment targeted the intestinal reservoirs of E. coli that survive antibiotic treatment of acute infections and can become increasingly resistant.
Promising results
The treatments were well tolerated and did not result in noticeable side effects. The two patients who received the combination therapy have experienced a long-term reduction of UTIs over the course of two years, while the one patient with PT only has experienced further episodes but with reduced symptoms. For all patients, quality of life improved significantly, while the need for antibiotic treatment was substantially reduced.
Register with The Microbiologist for more free articles
Get full access to all The Microbiologist articles from just £2.17 a month
“Three patients are not a sufficiently large sample to establish this new therapy, and control groups were lacking. However, this experience has helped to lay the foundation for a clinical trial in order to test the clinical utility of this treatment approach and make it more widely available and sustainable for patients,” comments Shawna McCallin.
“While phage therapy acts to remove the pathogen, FMT aims to restore a healthy microbiome, combining both immediate and long-term effects,” Lena Biehl from University Hospital Cologne adds.
The clinical trial is scheduled to begin in June 2027 at the participating institutions as part of the REPhRAME project, which is funded by the European Commission through the Horizon Europe funding programme.
No comments yet